Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib,

OBJECTIVE: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Systemic inflammation is proposed to play a fundamental role in the altered lipid metabolism associated with RA; however, the underlying mechanisms are unknown. We undertook this study to compare choleste...

Descripción completa

Detalles Bibliográficos
Autores principales: Charles‐Schoeman, Christina, Fleischmann, Roy, Davignon, Jean, Schwartz, Howard, Turner, Scott M., Beysen, Carine, Milad, Mark, Hellerstein, Marc K., Luo, Zhen, Kaplan, Irina V., Riese, Richard, Zuckerman, Andrea, McInnes, Iain B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024065/
https://www.ncbi.nlm.nih.gov/pubmed/25470338
http://dx.doi.org/10.1002/art.38974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024065/
https://www.ncbi.nlm.nih.gov/pubmed/25470338
http://dx.doi.org/10.1002/art.38974

Ejemplares similares